After Hours
$
1.20
Change
+0.03 +2.56%
Volume
Volume 1,611
Aug 12, 2022, 7:44 p.m.
Quotes are delayed by 20 min
Previous close
$ 1.20
$ 1.17
Change
-0.03 -2.50%
Day low
Day high
$1.16
$1.20

52 week low
52 week high
$0.84
$4.44

Market cap
$20.31M
Average volume
108,418
P/E ratio
N/A
Rev. per Employee
$330,405
EPS
-0.58
Dividend
N/A
Div yield
N/A
Ex dividend date
N/A
MarketWatch News on BIOC
-
Biocept stock price target cut to $4 from $5 at Maxim Group
- Tomi Kilgore
-
Biocept swings to Q4 profit on COVID-19 testing
- MarketWatch.com
-
Biocept stock price target raised to $2 from $1 at Maxim Group
- Tomi Kilgore
-
Biocept started at buy with $3 stock price target at Maxim Group
- Tomi Kilgore
-
Biocept initiated as buy with stock price target of $2.50 at Chardan Global Insights
- Ciara Linnane
Analyst Ratings
-
Benzinga's Top Upgrades, Downgrades For June 2, 2017
- Benzinga.com
-
- Benzinga.com
Other News on BIOC
-
- Edgar Online - (EDG = 10Q, 10K)
-
Biocept reports delay in filing of Q1 report on Form 10-Q
- Seeking Alpha
-
- Edgar Online - (EDG = 10Q, 10K)
-
Biocept taps veteran biotechnology executive as COO
- Seeking Alpha
-
Biocept appoints Samuel Riccitelli as interim president, CEO
- Seeking Alpha
-
- Edgar Online - (EDG = 10Q, 10K)
-
Notable earnings after Thursday's close
- Seeking Alpha
-
Biocept launches combined COVID-19 and influenza test
- Seeking Alpha
-
- Edgar Online - (EDG = 10Q, 10K)
-
Biocept EPS misses by $0.04, beats on revenue
- Seeking Alpha
-
Notable earnings after Monday's close
- Seeking Alpha
-
BHP, Petroleo Brasileiro, Roblox among premarket losers' pack
- Seeking Alpha
- Loading more headlines...
Press Releases on BIOC
-
Liquid Biopsy Market Share to Witness Steady Rise by 2029
- AmericaNewsHour
-
Biocept Appoints RSM as Independent Auditor
- BusinessWire - BZX
-
Biocept to Hold Business Strategy Conference Call Today
- BusinessWire - BZX
-
Biocept Reports First Quarter 2022 Financial Results
- BusinessWire - BZX
-
Biocept Announces a Delay in the Filing of its Quarterly Report on Form 10-Q
- BusinessWire - BZX
-
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- BusinessWire - BZX
-
Biocept Reports 2021 Fourth Quarter and Full Year Financial Results
- BusinessWire - BZX
-
Biocept Reports Unaudited 2021 Revenue and Year-End Cash Balance
- BusinessWire - BZX
-
Biocept Appoints Philippe Marchand as Chief Operating Officer
- BusinessWire - BZX
-
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- BusinessWire - BZX
- Loading more headlines...
Rates »
National averages from Bankrate.com
National averages from Bankrate.com
National averages from Bankrate.com